Sarah Silk
Clinical Trials Immunologist
Research
I work on the Clinical Trials conducted as part of the Blood-Stage Malaria Programme led by Professor Simon Draper.
This programme includes both Phase I safety and immunogenicity studies and Phase II controlled human malaria infection studies. My role focuses on the characterisation of human humoral and cellular immune responses to the candidate vaccines and malaria exposure against both Plasmodium falciparum and Plasmodium vivax.
Additionally, I work closely with collaborating field sites in Africa, to conduct Clinical Trials in a malaria-endemic setting.
Recent publications
-
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine
-
Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection.
Journal article
Flynn O. et al, (2021), Vaccines, 9
-
Mapping immune variation and var gene switching in naive hosts infected with Plasmodium falciparum
Journal article
Milne K. et al, (2021), eLife, 10
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Journal article
Voysey M. et al, (2021), The Lancet, 397, 881 - 891
-
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278